Business Description
Doseology Sciences Inc
NAICS : 541714
SIC : 3741
ISIN : CA2584841043
Compare
Compare
Traded in other countries / regions
MOOD.CanadaDOSEF.USAVU70.Germany IPO Date
2021-11-15Description
Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. Doseology offers cutting-edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 25.76 | |||||
Equity-to-Asset | 1 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 122.15 | |||||
Beneish M-Score | -4.71 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -57.3 | |||||
3-Year EPS without NRI Growth Rate | -15.6 | |||||
3-Year FCF Growth Rate | -55.7 | |||||
3-Year Book Growth Rate | 6.6 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 4.49 | |||||
9-Day RSI | 14.64 | |||||
14-Day RSI | 23.17 | |||||
6-1 Month Momentum % | 66.67 | |||||
12-1 Month Momentum % | -16.67 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 378.67 | |||||
Quick Ratio | 368.67 | |||||
Cash Ratio | 360.67 | |||||
Days Inventory | 369.15 | |||||
Days Sales Outstanding | 37.73 | |||||
Days Payable | 185.82 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 78.03 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 78.85 | |||||
Operating Margin % | -349.04 | |||||
Net Margin % | -1325 | |||||
FCF Margin % | -336.54 | |||||
ROE % | -95.34 | |||||
ROA % | -86.87 | |||||
ROIC % | -102.48 | |||||
ROC (Joel Greenblatt) % | -390.63 | |||||
ROCE % | -85.07 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 6.25 | |||||
PB Ratio | 0.58 | |||||
Price-to-Tangible-Book | 0.58 | |||||
EV-to-EBIT | 0.32 | |||||
EV-to-EBITDA | 0.33 | |||||
EV-to-Revenue | -4.06 | |||||
EV-to-FCF | 1.21 | |||||
Price-to-Net-Current-Asset-Value | 0.58 | |||||
Price-to-Net-Cash | 0.6 | |||||
Earnings Yield (Greenblatt) % | 312.5 | |||||
FCF Yield % | -53.03 |